Gosset Ownership
Private
Therapeutic Areas
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
AUM BioTech General Information
Provides validated self-delivering antisense technologies enabling robust gene silencing in vitro and in vivo without transfection reagents. Widely adopted by academic and industry researchers globally for target validation and mechanistic studies across multiple biomedical fields.[2][3][4]
Contact Information
Website
Primary Industry
Non-Drug Biotech
Corporate Office
Philadelphia, PA
USA
USA
Drug Pipeline
AUMsilence
CommercialKey Partnerships
A joint initiative with AUM LifeTech (“Knockdown Coronavirus” program); no major pharma partnerships disclosed.[3]
AUM BioTech Funding
No funding data available
To view AUM BioTech's complete valuation and funding history, request access »